Story perspectives

Study Finds FDA Followed Evidence on Mifepristone, Except Trump Era

1/12/2026

Summary

Story summary

A JAMA study by Johns Hopkins University researchers finds the FDA generally followed evidence-based recommendations on mifepristone from 2011 to 2023.
Dr. Caleb Alexander of Johns Hopkins University notes the FDA's decisions did not reflect bias toward either side of the abortion debate.
The study identifies one significant exception during the Trump administration.
The findings reflect ongoing political contention, with anti-abortion and pro-choice groups influencing FDA regulation.

1 of 1

Story summary

A JAMA study by Johns Hopkins University researchers finds the FDA generally followed evidence-based recommendations on mifepristone from 2011 to 2023.
Dr. Caleb Alexander of Johns Hopkins University notes the FDA's decisions did not reflect bias toward either side of the abortion debate.
The study identifies one significant exception during the Trump administration.
The findings reflect ongoing political contention, with anti-abortion and pro-choice groups influencing FDA regulation.